(Varying efficacy of helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model)
The value of eradicating helicobacter pylori in duodenal ulcer disease is well established but small differences in the efficacy of antibiotic regimens can have a big influence on the comparative cost effectiveness of eradication strategies.
In a commentary, Delany and Hobbs point out that prescribing for dyspepsia is now the largest single area of cost for primary care, 500 million per year in the United Kingdom in 1996. Although this covers non-ulcer dyspepsia as well as peptic ulcer disease, the size of the bill underlines the rationale for making cost-effectiveness part of the eradication strategy for H pylori.
Contact :
Prof Richard Logan, Department of Public Health and Epidemiology, University of Nottingham, Nottingham NG7 2UH
e-mail : richard.logan@nottingham.ac.uk
'"/>
Contact: Jill Shepherd
jshepher@bma.org.uk
+44 171 383 6254
BMJ-British Medical Journal
29-May-1998